Research programme: heparanase inhibitors - TBG Diagnostics Limited
Alternative Names: PG 500 series; PG 562Latest Information Update: 16 Jul 2016
At a glance
- Originator Progen Pharmaceuticals
- Developer Griffith University; Progen Pharmaceuticals Limited
- Class Oligosaccharides; Proteoglycans; Small molecules
- Mechanism of Action Heparanase inhibitors; Intercellular signalling peptide and protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
- Discontinued Asthma; Autoimmune disorders; Inflammatory bowel diseases; Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Australia (PO)
- 15 Jul 2010 Preclinical trials in Cancer in Australia (PO)